Nudge to Gynecologic Oncology
NCT06451263 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-09-19
Summary
Ovarian cancer lacks an effective screening test, and prompt treatment at diagnosis is the only way to improve outcomes. Referral to gynecologic oncology at diagnosis of adnexal mass is recommend by guidelines from every major medical organization. Yet, 1 in 4 patients with ovarian cancer nationwide and at Penn Medicine never see a gynecologic oncologist. Even when referred to gynecologic oncology, patients from historically-marginalized groups have twice as long duration from diagnosis to seeing gynecologic oncology. In this project, the investigators will pilot a clinician nudge to gynecologic oncology referral and compare the impact to historical controls.
Conditions
- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer
Interventions
- BEHAVIORAL
-
Nudge
Referral to gynecologic oncology is recommended when patients are diagnosed with a complex adnexal mass on imaging (i.e., O-RADS 4 or 5 on ultrasound or MRI, Codex 4 or 5 on CT). When patients are identified as having an adnexal mass, the order will be pended by the clinical research coordinator and sent to the ordering provider with a message to sign. The order will be pended within 48 hours of resulting imaging. The message will include content about national guidelines on referral to gynecologic oncology with opt-out framed language.
Sponsors & Collaborators
-
Abramson Cancer Center at Penn Medicine
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-19
- Primary Completion
- 2024-04-24
- Completion
- 2027-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT00267696 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01372787 ·Status: UNKNOWN
-
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00958698 ·Status: UNKNOWN ·Phase: NA
-
Neoadjuvant Therapy for Ovarian Cancer
NCT01146795 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer
NCT03656809 ·Status: COMPLETED
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
NCT00003382 ·Status: TERMINATED ·Phase: PHASE1
-
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
NCT01468909 ·Status: COMPLETED ·Phase: PHASE2
-
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
NCT05446298 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer
NCT02406235 ·Status: COMPLETED
-
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
NCT03150121 ·Status: UNKNOWN ·Phase: NA
-
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
NCT03367260 ·Status: COMPLETED
-
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
NCT00191646 ·Status: COMPLETED ·Phase: PHASE3
-
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00288275 ·Status: TERMINATED
-
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
NCT01366183 ·Status: UNKNOWN
-
Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer
NCT00352300 ·Status: COMPLETED ·Phase: PHASE1
-
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
NCT04204811 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01081262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
NCT06312124 ·Status: RECRUITING ·Phase: NA
-
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01167712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296 ·Status: RECRUITING ·Phase: PHASE2
-
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
NCT00897039 ·Status: UNKNOWN
-
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
NCT04701645 ·Status: RECRUITING ·Phase: PHASE1
-
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02101775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2